Issues in the Pharmaceutical Industry
Global Pharma Industry
Opportunity
Obstacle
New Technologies
New Markets
Biomarkers
Molecular advances
Controversy e.g. Gardasil
Politics
Regulatory
Global Market Growth
2014/15 = 9% CAGR
Why?*
Hepatitis C
Cancer
2016-21 = 4-7% CAGR
Medicines Consumed +3% 2021
Issues to Market Growth
Pricing
Generics
Market Access
Lower volume growth in emerging markets
In Ireland
Roche
Gilead
AbbVie
US Pharma Market
Largest Pharma Market
Crucial to overall Pharma Performance
6-9% - 2021
Will account for 53% Of Global Growth
WHY?
End of Hep C related growth
Patent Expiries
Increase intro of biosimilars
Healthcare
Ireland
US
Government spending Vs. Drug Cost
Reimbursement of the HSE
Medicine Shortage
2010 = Reform and increase market for Pharma products
new admin = potential to decrease
Irish Healthcare
Medicine out of Stock = 140
Healthcare Expense 2017 = 14.6 billion
Doubled in cost = High Tech Meds
New Technologies
Biosimilars
Artificial Intelligence
3D Printing
Precision Medicine
mHealth sensors
Nanotechnology
Landmark Decision allows biosimilar makers to give marketing notice before FDA approval, meaning their products can launch faste
Emerging Markets = Vol growth driven by generics
Patient focused healthcare
challenging reimbursement
regulatory environments
new trends in consumerism
required to
show value for money
satisfy regulators
Justify prices